Skip to content

Katie Ellias

Managing Director

Katie Ellias

JDRF T1D Fund

Managing Director

Katie Ellias joined the T1D Fund in July 2018 as a Managing Director. She serves on the board of Fund portfolio companies Veralox, i2O, Capillary Bio, Biolinq, Inversago, and Protomer. Katie joined from Endeavour Vision, a Geneva-based growth stage venture fund, where she focused on medical devices and digital health as Senior Investment Director. She was previously Principal at Sofinnova Partners, Paris, a leading early stage life sciences fund, investing in medical technologies. She served on the boards of ReCor Medical (sold to Otsuka Holdings), Shockwave Medical (NASDAQ: SWAV), and RefleXion Medical. Prior to VC, Katie held roles in Business Development, Sales and Marketing at Medtronic in the Cardiac and Vascular businesses. She began her career at McKinsey & Company and Partners Healthcare in Boston. Katie holds a M.B.A. in Healthcare Management from the Wharton School at the University of Pennsylvania and a B.A. cum laude in International Relations and Political Science from Yale University.